Latest news and press releases about Corbus Pharmaceuticals Holdings, Inc. (CRBP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid typ...
Price
| Price | $7.26 |
| Market Cap | $135M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.40 |
| EV / EBITDA | -1.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -87.05% |
| Return on Invested Capital | -100.35% |
| Return on Assets | -80.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRDF · ELTX · FBRX · IPHA · MIST
Explore sector: Healthcare · Biotechnology
More sections of CRBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks